Tags

Type your tag names separated by a space and hit enter

CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin.
Cell Death Differ 2000; 7(9):785-94CD

Abstract

Owing to its lineage and differentiation stage-restricted expression, CD77 has been mooted as a therapeutic target in Burkitt lymphoma (BL). The recognition that the globotriaosyl moiety of this neutral glycosphingolipid is a receptor for Escherichia coli-derived Verotoxin-1 (Shiga-Like Toxin-1) offers a potential delivery system for the attack. Here we show that CD77-expressing Group I BL cells which are normally susceptible to activation-induced death on binding Verotoxin-1 B chain are protected in the presence of CD40 ligand. Ectopic expression of either bcl-2 or bcl-xL also afforded resistance to the actions of the B chain. In total contrast, neither of the survival genes nor a CD40 signal - even when acting in concert - protected against killing mediated by the holotoxin. These findings indicate that while therapeutic modalities for CD77-expressing B cell tumors (which include follicular lymphoma) based on the use of Verotoxin-1 B chain might be compromised by the activation of endogenous or exogenous survival pathways, those exploiting the holotoxin should be left unscathed.

Authors+Show Affiliations

MRC Centre for Immune Regulation, The University of Birmingham, Birmingham, UK. j.gordon@bham.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11042673

Citation

Gordon, J, et al. "CD40 Ligand, Bcl-2, and Bcl-xL Spare Group I Burkitt Lymphoma Cells From CD77-directed Killing Via Verotoxin-1 B Chain but Fail to Protect Against the Holotoxin." Cell Death and Differentiation, vol. 7, no. 9, 2000, pp. 785-94.
Gordon J, Challa A, Levens JM, et al. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin. Cell Death Differ. 2000;7(9):785-94.
Gordon, J., Challa, A., Levens, J. M., Gregory, C. D., Williams, J. M., Armitage, R. J., ... Lord, J. M. (2000). CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin. Cell Death and Differentiation, 7(9), pp. 785-94.
Gordon J, et al. CD40 Ligand, Bcl-2, and Bcl-xL Spare Group I Burkitt Lymphoma Cells From CD77-directed Killing Via Verotoxin-1 B Chain but Fail to Protect Against the Holotoxin. Cell Death Differ. 2000;7(9):785-94. PubMed PMID: 11042673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin. AU - Gordon,J, AU - Challa,A, AU - Levens,J M, AU - Gregory,C D, AU - Williams,J M, AU - Armitage,R J, AU - Cook,J P, AU - Roberts,L M, AU - Lord,J M, PY - 2000/10/24/pubmed PY - 2001/2/28/medline PY - 2000/10/24/entrez SP - 785 EP - 94 JF - Cell death and differentiation JO - Cell Death Differ. VL - 7 IS - 9 N2 - Owing to its lineage and differentiation stage-restricted expression, CD77 has been mooted as a therapeutic target in Burkitt lymphoma (BL). The recognition that the globotriaosyl moiety of this neutral glycosphingolipid is a receptor for Escherichia coli-derived Verotoxin-1 (Shiga-Like Toxin-1) offers a potential delivery system for the attack. Here we show that CD77-expressing Group I BL cells which are normally susceptible to activation-induced death on binding Verotoxin-1 B chain are protected in the presence of CD40 ligand. Ectopic expression of either bcl-2 or bcl-xL also afforded resistance to the actions of the B chain. In total contrast, neither of the survival genes nor a CD40 signal - even when acting in concert - protected against killing mediated by the holotoxin. These findings indicate that while therapeutic modalities for CD77-expressing B cell tumors (which include follicular lymphoma) based on the use of Verotoxin-1 B chain might be compromised by the activation of endogenous or exogenous survival pathways, those exploiting the holotoxin should be left unscathed. SN - 1350-9047 UR - https://www.unboundmedicine.com/medline/citation/11042673/CD40_ligand_Bcl_2_and_Bcl_xL_spare_group_I_Burkitt_lymphoma_cells_from_CD77_directed_killing_via_Verotoxin_1_B_chain_but_fail_to_protect_against_the_holotoxin_ L2 - http://dx.doi.org/10.1038/sj.cdd.4400710 DB - PRIME DP - Unbound Medicine ER -